5-ethynyl-2-pyridyl, 4-chloro-5-fluoro-2-pyridyl, 5-chloro-4-fluoro-2-pyridyl, 5-chloro-3-pyridyl, 5-fluoro-3-pyridyl, 5-bromo-3-pyridyl, 5-ethynyl-3-pyridyl, 6-chloro-3-pyridazinyl, 6-fluoro-3-pyridazinyl, 6-bromo-3-pyridazinyl, 6-ethynyl-3-pyridazinyl, 5-chloro-2-thiazolyl, 5-fluoro-2-thiazolyl, 5-bromo-2-thiazolyl or 5-ethynyl-2-thiazolyl.

11. The compound according to claim 1 wherein Q^1 is 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl, 5-cyclopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl, 5-carboxymethyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl, 5-butyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl, 5-(4-pyridyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]-pyridin-2-yl, 5-methyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridine-2-yl, 6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-2-yl, 5-methyl-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine-2-yl, 5-methyl-4,6-dihydro-5H-pyrrolo[3,4-d]thiazol-2-yl, 5,7-dihydro-6-methylpyrrolo[3,4-d]pyridazin-2-yl, 5,6-dimethyl-4,5,6,7-tetrahydrothiazolo[4,5-d]pyridazin-2-yl, 5,6-dimethyl-4,5,6,7-tetrahydrooxazolo[4,5-d]pyridazin-2-yl, 5-dimethylamino-4,5,6,7-tetrahydrobenzo[d]thiazol-2-yl, 5-(4-pyridyl)-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl or 6,7-dihydro-4H-pyrano[4,3-d]thiazol-2-yl.

~~12. A medicine comprising the compound, the salt~~

thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~.

~~13.~~ An activated blood coagulation factor X inhibitor comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~.

~~14.~~ An anticoagulant comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~.

~~15.~~ An agent for preventing and/or treating thrombosis or embolism, comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~.

~~16.~~ An agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing, comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~.

~~17.~~ A medicinal composition comprising the compound,

the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~, and a pharmaceutically acceptable carrier.

~~18.~~ Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~ for preparation of a medicine.

~~19.~~ Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~ for preparation of an activated blood coagulation factor X inhibitor.

~~20.~~ Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~ for preparation of an anticoagulant.

~~21.~~ Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~ for preparation of an agent for preventing and/or treating thrombosis or embolism.


~~22.~~ Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to ~~11~~ for preparation of an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and

reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

~~23.~~ A compound represented by the following general formula (4):

$$HN(R^1)-Q^3-N(R^2)-T^1-Q^4 \qquad (4)$$

wherein R^1, R^2, T^1 and Q^4 have the same meanings as defined in claim 1, Q^3 represents the following group:




wherein Q^5, R^3 and R^4 have the same meanings as defined in claim 1.

~~24.~~ A compound represented by the following general formula (9):

$$Q^1-Q^2-C(=O)-N(R^1)-Q^3-NHR^2 \qquad (9)$$


wherein Q^1, Q^2, R^1 and R^2 have the same meanings as defined in claim 1, and Q^3 represents the following group:




in which Q^5, R^3 and R^4 have the same meanings as defined in claim 1, a salt thereof, a solvate thereof, or an N-oxide thereof.

~~25.~~ The compound according to claim 1, wherein T^1 represents -C(=O)-C(=O)-NH-, -C(=S)-C(=O)-NH-, -C(=S)-C(=S)-NH- or -C(=O)-C(=S)-NH-.


12. The compound, the salt thereof, or the hydrate thereof according to claim 1, which is N^1-(5-chloropyridin-2-yl)-N^2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl)carbonyl]amino}cyclohexyl)ethanediamide of the following formula, a salt thereof, or a hydrate thereof:



13. The compound, the salt thereof, or the hydrate thereof according to claim 1, which is N^1-(5-chloropyridin-2-yl)-N^2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate:



14. N^1-(5-chloropyridin-2-yl)-N^2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-toluenesulfonate monohydrate:



p-toluenesulfonate monohydrate.

15. A medicine comprising the compound, the salt

thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14.

16. An activated blood coagulation factor X inhibitor comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14.

17. An anticoagulant comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14.

18. An agent for preventing and/or treating thrombosis or embolism, comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14.

19. An agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing, comprising the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14.

20. A medicinal composition comprising the compound,

the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14, and a pharmaceutically acceptable carrier.

21. Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14 for preparation of a medicine.

22. Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14 for preparation of an activated blood coagulation factor X inhibitor.

23. Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14 for preparation of an anticoagulant.

24. Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14 for preparation of an agent for preventing and/or treating thrombosis or embolism.


25. Use of the compound, the salt thereof, the solvate thereof, or the N-oxide thereof according to any one of claims 1 to 14 for preparation of an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and

reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

26. A compound represented by the following general formula (4):

$$HN(R^1)-Q^3-N(R^2)-T^1-Q^4 \qquad (4)$$

wherein R^1, R^2, T^1 and Q^4 have the same meanings as defined in claim 1, Q^3 represents the following group:




wherein Q^5, R^3 and R^4 have the same meanings as defined in claim 1.

27. A compound represented by the following general formula (9):

$$Q^1-Q^2-C(=O)-N(R^1)-Q^3-NHR^2 \qquad (9)$$

wherein Q^1, Q^2, R^1 and R^2 have the same meanings as defined in claim 1, and Q^3 represents the following group:



in which Q^5, R^3 and R^4 have the same meanings as defined in claim 1, a salt thereof, a solvate thereof, or an N-oxide thereof.

28. The compound according to claim 1, wherein T^1 represents -C(=O)-C(=O)-NH-, -C(=S)-C(=O)-NH-, -C(=S)-C(=S)-NH- or -C(=O)-C(=S)-NH-.